Last reviewed · How we verify
GT101 Injection for the Treatment of Metastatic or Recurrent Solid Tumors
This is a multicenter, single-arm phase I clinical trial.The study process was divided into: screening period, sampling and production period, lymphodepleting chemotherapy period, treatment and observation period, and follow-up period. The study is designed to enroll 20-31 subjects, with 14-20 subjects expected to be evaluable, in an "autologous tumor-infiltrating lymphocyte therapy" regimen that includes： 1. Clear lymphatic pretreatment (FC regimen: cyclophosphamide + fludarabine). 2. GT101 infusion. 3. post-infusion treatment (interleukin-2 intravenous push).
Details
| Lead sponsor | Grit Biotechnology |
|---|---|
| Phase | PHASE1 |
| Status | RECRUITING |
| Enrolment | 31 |
| Start date | Mon May 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jun 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Solid Tumors, Adult
Interventions
- GT101
Countries
China